Editorial Office, Precision Cancer Medicine. Email: email@example.com
On June 26, 2021, we received the good news from Elsevier that Precision Cancer Medicine (PCM) has been accepted for inclusion in Scopus.
PCM (ISSN: 2617-2216) is an international, peer-reviewed journal dedicated to precise diagnosis and treatment of cancers and personalized care for patients, encompassing areas of oncology, pathology, imaging, radiotherapy, chemotherapy, surgery, anesthesiology, nursing and etc. Led by Dr. Xiaomao Guo as the Editor-in-Chief, PCM is further supported by a strong lineup of over 200 experts worldwide as the Editorial Board members. PCM provides a professional platform for colleagues around the world to share advanced research results, up-to-date knowledge and unique experiences in the emerging field of precision and personalized medicine to fight cancers.
We can’t achieve this without the continuous support and contributions of PCM’s editorial board members, guest editors, authors, reviewers and readers. We here would like to extend our sincere gratitude to all the contributors. We will keep striving to publish high-quality articles and make PCM to the forefront.